MET and lung carcinoma: E7050, a dual inhibitor of Met and vascular endothelial growth factor receptor two kinase, and EGFR-TKIs suppressed tumor progression in erlotinib-resistant cancer cell lines and in HGF-induced EGFR-TKI-resistant lung cancer cell lines that also have a mutation in EGFR [12, 13].